Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 19/20 | 0.85 |
| ▸ | AURKA | O14965 | 8/20 | 0.81 |
| ▸ | PLK1 | P53350 | 4/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.72 |
| ▸ | CDK2 | P24941 | 3/20 | 0.72 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.72 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.64 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559619 | 1.00 | TTK (0.85) | TTKAURKAPLK1CCNA2CDK2 | |
| Phosphoric Acid SCHEMBL20599169 | 0.98 | TTK (0.82) | TTKAURKAPLK1CCNA2CDK2 | |
| Phosphoric Acid SCHEMBL29732994 | 0.98 | TTK (0.82) | TTKAURKAPLK1CCNA2CDK2 | |
| SCHEMBL15377650 | 0.96 | TTK (0.89) | TTKAURKAPLK1CCNA2CDK2 | |
| SCHEMBL1558564 | 0.96 | TTK (0.81) | TTKAURKAPLK1CCNA2CDK2 | |
| SCHEMBL1559628 | 0.96 | TTK (0.81) | TTKAURKAPLK1CCNA2CDK2 | |
| SCHEMBL22287182 | 0.96 | TTK (0.78) | TTKAURKAPLK1CCNA2CDK2 | |
| SCHEMBL15377685 | 0.92 | TTK (0.82) | TTKAURKAPLK1CCNA2CDK2 | |
| SCHEMBL1559641 | 0.92 | TTK (1.00) | TTKAURKAPLK1CCNA2CDK2 | |
| SCHEMBL1893861 | 0.92 | TTK (0.71) | TTKAURKAPLK1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4506015-A1 | COMBINATION OF A MPS1 INHIBITOR AND AN ANTIBODY DRUG CONJUGATE | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-12 | — | — | EP | claimed |
| WO-2025002962-A1 | USE OF A MPS1 INHIBITOR FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-01-02 | — | — | WO | claimed |
| WO-2025032079-A1 | COMBINATION OF A MPS1 INHIBITOR AND AN ANTIBODY DRUG CONJUGATE | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-02-13 | — | — | WO | disclosed |
| EP-4506015-A1 | COMBINATION OF A MPS1 INHIBITOR AND AN ANTIBODY DRUG CONJUGATE | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-12 | — | — | EP | disclosed |
| EP-4506015-A1 | COMBINATION OF A MPS1 INHIBITOR AND AN ANTIBODY DRUG CONJUGATE | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-12 | — | — | EP | disclosed |
| WO-2025021587-A1 | COMBINATION OF A MPS1 INHIBITOR AND IMMUNE CHECKPOINT INHIBITORS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025002962-A1 | USE OF A MPS1 INHIBITOR FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-01-02 | — | — | WO | disclosed |
| CN-110896636-B | Salts of compounds that inhibit MPS1 kinase, preparation thereof and formulations comprising the same | 内尔维亚诺医疗科学公司 | 2022-07-19 | — | — | CN | disclosed |